Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
58 hedge funds and large institutions have $39.6M invested in Carisma Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 3 closing their positions.
212% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $786K
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
9% more funds holding
Funds holding: 53 → 58 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.55% less ownership
Funds ownership: 23.8% → 23.25% (-0.55%)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
53% less capital invested
Capital invested by funds: $84M → $39.6M (-$44.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.14M |
| 2 |
Renaissance Technologies
New York
|
+$651K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$322K |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$99.9K |
| 5 |
SG Americas Securities
New York
|
+$86.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TOTUOP
Trustees of The University of Pennsylvania
Philaldelphia,
Pennsylvania
|
-$2.68M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$229K |
| 3 |
BlackRock
New York
|
-$186K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$134K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$130K |
CARM Hedge Fund Activity: Q3 2023 in Review
58 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2023, worth a combined $39.6M — down 53% from $84M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CARM positions and 3 closed out — a net gain of 6 holders — while 14 added to existing stakes and 17 trimmed.
The largest buyer was Arrowstreet Capital, opening a new position worth an estimated $1.14M. The largest seller was Trustees of The University of Pennsylvania, cutting an estimated $2.68M.
- 58 institutional investors held Carisma Therapeutics (CARM) as of Q3 2023, up from 53 in Q2 2023.
- Funds reported $39.6M of Carisma Therapeutics stock for Q3 2023, down 53% quarter-over-quarter.
- 9 funds opened new Carisma Therapeutics positions in Q3 2023 and 3 closed out, a net change of +6 holders.
- The largest Carisma Therapeutics buyer in Q3 2023 was Arrowstreet Capital, an estimated $1.14M added.
- The largest Carisma Therapeutics seller in Q3 2023 was Trustees of The University of Pennsylvania, an estimated $2.68M sold.
Based on aggregated 13F filings for Q3 2023.